PHBI - My No. 1 Biotech Stock For 2020
Multiple Catalysts Could Provide Fuel For This Profile's Immediate Launch (Key Details Below)
Now is the time to turn your full attention to a new breakout stock idea: Pharmagreen Biotech (Ticker: PHBI).
Pharmagreen is a biotech sciences company with specialized products and services in the can*nab*is ("CB") industry.
Like several of your previous triple-digit intraday runners over the past month, PHBI has very few shares available for trading.
Currently, OTCMarkets.com reports PHBI to have a minuscule 2.2Mn unrestricted shares.
Volatility could become a major player if certain catalysts drive momentum into this stock profile.
In fact, 3 specific catalysts highlighted in Thursday's PHBI press release could lead to this stock's immediate breakout. Read them below:
3 Catalysts Providing Significant Potential PHBI Growth
From Thursday 12/12's PR:
CARSON CITY, NV, Dec. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to provide a company development update. The company has secured significant credit facility to date and plans to use the funds to move forward with its projects development to build a state of the art all year round greenhouse and a tissue cultured starter plantlet production facility. The all year round greenhouse was added to the company’s plans for a first build out as time to complete construction is less than six months and revenue producing within 3 months of operations. The greenhouse will allow the company to earn revenues while the tissue culture facility is under construction.
Important Catalyst Takeaways From PHBI's Press Release
#1. Securing a substantial line of credit, PHBI will look to push forward its company's growth plan.
#2. Development plans of their 24/7/365 production facility are in motion.
#3. When PHBI completes construction of the greenhouse in 6 months, it will only take an additional 3 months to start earning revenues.
Rated as my Number #1 Biotech profile, you can now see why I've given PHBI this label...
KEY DETAIL - The Pharmagreen Botany Centre is dedicated to breaking boundaries to become the most internationally recognized and valued biotech science solutions company in North America for its proprietary micro-propagation techniques, tissue culture plantlets production, research and development for plants sustainability, preservation of genetics, extraction of botanical oils, CB products development and plant DNA species identification and certification center.
To wrap it up and put a bow on it, Pharmagreen is a science driven and backed company that views their produced products as unparalleled.
Pharmagreen's model is to provide the hemp farmers the highest quality starter female plantlets to produce the highest quality biomass for the production of CB formulations for human and animal use.
Pharmagreen's ability to supply high CB starter plantlets paired with high level of expertise in farming the strain provides a very lucrative, high CB hemp farming opp. for farmers by making highly efficient use of land.
Now, here's the best part...
IMPORTANT - Greater revenue and higher yields can be generated from 10 acres with Pharmagreen's high CB strain and farming techniques than from farming 1,000 acres using standard industrial hemp from seed.
If you just scanned that last paragraph, you need to go back. That info is bonkers!
By the way, did you know: The global industrial hemp market is projected to grow from $4.6Bn USD in 2019 to $26.6Bn USD by 2025, recording a CAGR of 34%.
With that type of growth potential in the global industrial hemp market, wouldn't farmers looking to produce CB from hemp want to maximize their output and product quality while minimizing the amount of land they use for their crops?
If you said no to that question, you might need have your head examined!
That's why I think that PHBI is currently flying under-the-radar and could be the next big breakout idea within the "Green Wave" movement.
2 More Catalysts That Could Send PHBI Shares Soaring In The Near-term
No. 1. (10/4/19) Pharmagreen Biotech is Seeking to Revolutionize Cancer Research and More with Their Botany Center
The CB industry is worth billions, and is showing no signs of slowing down with many CB related companies now providing crowdfunding investment opp's to both accredited and non-accredited inve*stors who wish to participate in its growth. It may also help discover cures and treatments for cancer. Pharmagreen Biotech, with their S1 document now effective from the SEC, is one such company targeting cancer research and much more with their vision of multi-purpose CB Botany Centers.
No. 2. (9/24/19) Pharmagreen Signs a LOI for Supply of CB Dana Hemp Starter Plantlets
Pharmagreen Biotech, Inc. is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has signed a Letter of Intent with Carpere Inc. for the supply of “CB Dana” hemp starter plantlets for the 2020 farming season and beyond.
The Pharmagreen team is excited to work with Carpere to be their supplier of all female high CB hemp starter plantlets to produce the highest quality high CB flower tops as well as production of the CB whole hemp oils and isolate. Carpere owns and manages farmland, on behalf of farmers, in excess of 100,000 acres throughout Canada.